4.6 Article

Reducing ventilator-associated pneumonia in intensive care: Impact of implementing a care bundle

期刊

CRITICAL CARE MEDICINE
卷 39, 期 10, 页码 2218-2224

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0b013e3182227d52

关键词

antimicrobials; care bundles; nosocomial infection; quality improvement; ventilator-associated pneumonia

资金

  1. Chief Scientist Office [CAF/08/13]
  2. National Health Service Lothian
  3. Eli Lilly
  4. Kimberley Clark
  5. Astra Zeneca
  6. Wyeth Pharmaceuticals
  7. Chief Scientist Office [CAF/08/13] Funding Source: researchfish
  8. Medical Research Council [G0901697] Funding Source: researchfish
  9. MRC [G0901697] Funding Source: UKRI

向作者/读者索取更多资源

Objectives: Ventilator-associated pneumonia is the most common intensive care unit-acquired infection. Although there is widespread consensus that evidenced-based interventions reduce the risk of ventilator-associated pneumonia, controversy has surrounded the importance of implementing them as a bundle of care. This study aimed to determine the effects of implementing such a bundle while controlling for potential confounding variables seen in similar studies. Design: A before-and-after study conducted within the context of an existing, independent, infection surveillance program. Setting: An 18-bed, mixed medical-surgical teaching hospital intensive care unit. Patients: All patients admitted to intensive care for 48 hrs or more during the periods before and after intervention. Interventions: A four-element ventilator-associated pneumonia prevention bundle, consisting of head-of-bed elevation, oral chlorhexidine gel, sedation holds, and a weaning protocol implemented as part of the Scottish Patient Safety Program using Institute of Health Care Improvement methods. Measurements and Main Results: Compliance with head-of-bed elevation and chlorhexidine gel were 95%-100%; documented compliance with wake and wean elements was 70%, giving overall bundle compliance rates of 70%. Compared to the preintervention period, there was a significant reduction in ventilator-associated pneumonia in the postintervention period (32 cases per 1,000 ventilator days to 12 cases per 1,000 ventilator days; p < .001). Statistical process control charts showed the decrease was most marked after bundle implementation. Patient cohorts staying >= 6 and >= 14 days had greater reduction in ventilator-associated pneumonia acquisition and also had reduced antibiotic use (reduced by 1 and 3 days; p = .008/.007, respectively). Rates of methicillin-resistant Staphylococcus aureus acquisition also decreased (10% to 3.6%; p < .001). Conclusions: Implementation of a ventilator-associated pneumonia prevention bundle was associated with a statistically significant reduction in ventilator-associated pneumonia, which had not been achieved with earlier ad hoc ventilator-associated pneumonia prevention guidelines in our unit. This occurred despite an inability to meet bundle compliance targets of 95% for all elements. Our data support the systematic approach to achieving high rates of process compliance and suggest systematic introduction can decrease both infection incidence and antibiotic use, especially for patients requiring longer duration of ventilation. (Crit Care Med 2011; 39:2218-2224)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据